Immuno-Oncology Technology

LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

P.A. Jänne, E.F. Smit, F. de Marinis et al. · 2022 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial

Maartje W. Rohaan, Raquel Gomez-Eerland, Joost H. van den Berg et al. · 2022 · 40 citations · Full text

Medicine, Immunology, Oncology +17

Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors

Marcel A. Deken, Karolina Niewola‐Staszkowska, Olivier Peyruchaud et al. · 2023 · 23 citations · Full text

Medicine, Oncology, Pharmacology +11

1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

Enriqueta Felip, M. Srivastava, Martin Reck et al. · 2022 · 20 citations · Full text

Medicine, Oncology, Surgery +16

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit

Inez Johanna, Annet Daudeij, Farah Devina et al. · 2023 · 17 citations · Full text

Pharmacy, Immunology, Pharmacology +17